Novartis Investigative Site

Koto-ku, Tokyo 136-0075

0 studies enrolling now · 20 studies all time

What they study most

ALK Positive Malignancies, Advanced Non Small Cell Lung Cancer (NSCLC), Advanced Solid Tumors, Advanced or Metastatic ER+ Breast Cancer, Breast Cancer, Cancer of Lung, Cancer of the Lung, Carcinoma, Colorectal, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chordoma and Alveolar Soft Part Sarcoma, DLBCL, Diffused Large B Cell Lymphoma

Studies at this site

• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation — Running, not enrolling
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies — Stopped early
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. — Stopped early
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib — Completed
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma — Stopped early
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) — Completed
• A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors — Stopped early
• Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers — Stopped early
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies — Completed
• Dose Range Finding Study of Bimagrumab in Sarcopenia — Completed
• PCA062 in pCAD-positive Tumors. — Completed
• Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor — Completed
• A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study — Completed
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations — Stopped early
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer — Completed
• Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women — Completed
• Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy — Stopped early